Post-Marketing surveillance for HPV infection related serious disease in a cohort of Chinese women who received GARDASIL® and GARDASIL®9

10/07/2020
02/07/2024
EU PAS number:
EUPAS36135
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

V503-056_Redacted Protocol red

English (9.45 MB - PDF) View document
Study results
Study results

V503-056-CSR- HPV PMC G9 effectiveness study report_final redaction

English (1.06 MB - PDF) View document

V503-056_Combined G4 and G9 Report with Cover Letter_final redaction

English (1.29 MB - PDF) View document
Study report
Other information